Thermo Fisher Scientific
RANK
92
A leading provider of life-science-related equipment and services to pharmaceutical, biotech, and government entities, Thermo Fisher Scientific rode a wave of demand in the second year of the pandemic: Among other things, companies making COVID vaccines and treatments continue to rely on its lab equipment. Revenue and profits each grew more than 20% in 2021.
Eric Lalmand—Belga/AFP/Getty Images
Company Information
As of 2/1/2023
Country
U.S.
Headquarters
Waltham, Mass.
Industry
Medical Products and Equipment
CEO
Marc N. Casper
Website
Company Type
Public
Ticker
TMO
Revenues ($M)
$44,915
Profits ($M)
$6,950
Market Value ($M)
$232,831
Employees
129,000
Figures are for fiscal year ended Dec. 31, 2022. Market value as of Jan. 20, 2023. Sources: Bloomberg; S&P Global.
Key Financials (Last Fiscal Year)
$ millions
% change
Revenues ($M)
$39,211
21.7%
Profits ($M)
$7,725
21.2%
Assets ($M)
$95,123
-
Total Stockholder Equity ($M)
$40,793
-
Profit Ratios
Profit as % of Revenues
19.7%
Profits as % of Assets
8.1%
Profits as % of Stockholder Equity
18.9%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)
1,946
EPS % Change (from 2020)
21.9%
EPS % Change (5 year annual rate)
30.8%
EPS % Change (10 year annual rate)
18.9%
Total Return
Total Return to Investors (2021)
43.5%
Total Return to Investors (5 year, annualized)
36.8%
Total Return to Investors (10 year, annualized)
31.5%
Thermo Fisher Scientific Rank History
Historical Data
| Year | Revenues ($M) | Profits ($M) | Assets ($M) | Total Stockholder Equity ($M) |
|---|---|---|---|---|
| 2021 | $32,21826.1% | $6,37572.5% | $69,052 | $34,507 |
| 2020 | $25,5424.9% | $3,69625.8% | $58,381 | $29,675 |
| 2019 | $24,35816.4% | $2,93832.0% | $56,232 | $27,586 |
| 2018 | $20,91814.5% | $2,22510.1% | $56,669 | $25,413 |
| 2017 | $18,2747.7% | $2,021.82.3% | $45,908 | $21,539 |
SHOW MORE
Lists ranking Thermo Fisher Scientific
